Amicus Therapeutic’s Fabry treatment meets goals in late-stage trial

Shares surge 40% in premarket trade on positive news from Phase 3 study.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.